Skip to main content Skip to footer
HomeHome
 
  • Homepage
  • Searching for patents

    Patent knowledge

    Access our patent databases and search tools.

    Go to overview 

    • Overview
    • Technical information
      • Overview
      • Espacenet - patent search
      • European Publication Server
      • Searching Asian documents: patent search and monitoring services
      • EP full-text search
      • Bibliographic coverage in Espacenet and OPS
      • Full-text coverage in Espacenet and OPS
    • Legal information
      • Overview
      • European Patent Register
      • European Patent Bulletin
      • European Case Law Identifier sitemap
      • Searching Asian documents
      • Third-party observations
    • Business information
      • Overview
      • PATSTAT
      • IPscore
      • Patent insight reports
    • Data
      • Overview
      • Linked open EP data
      • Bulk data sets
      • Web services
      • Coverage, codes and statistics
    • Helpful resources
      • Overview
      • First time here?
      • Asian patent information
      • Patent information centres
      • Patent Translate
      • Patent Knowledge News
      • Business and statistics
      • Unitary Patent information in patent knowledge

    UP search

    Learn about the Unitary Patent in patent knowledge products and services

  • Applying for a patent

    Applying for a patent

    Practical information on filing and grant procedures.

    Go to overview 

    • Overview
    • European route
      • Overview
      • European Patent Guide
      • Oppositions
      • Oral proceedings
      • Appeals
      • Unitary Patent & Unified Patent Court
      • National validation
      • Request for extension/validation
    • International route (PCT)
      • Overview
      • Euro-PCT Guide – PCT procedure at the EPO
      • EPO decisions and notices
      • PCT provisions and resources
      • Extension/validation request
      • Reinforced partnership programme
      • Accelerating your PCT application
      • Patent Prosecution Highway (PPH)
      • Training and events
    • National route
    • MyEPO services
      • Overview
      • Understand our services
      • Get access
      • Find a professional representative
      • File with us
      • Interact on your files
      • Online Filing & fee payment outages
      • Tutorials
    • Forms
      • Overview
      • Request for examination
    • Fees
      • Overview
      • European fees (EPC)
      • International fees (PCT)
      • Unitary Patent fees (UP)
      • Fee payment and refunds
      • Warning

    UP

    Unitary Patent

  • Law & practice

    Law & practice

    European patent law, the Official Journal and other legal texts.

    Go to overview 

    • Overview
    • Legal texts
      • Overview
      • European Patent Convention
      • Official Journal
      • EPC Guidelines
      • PCT-EPO Guidelines
      • Guidelines revision cycle
      • Extension / validation system
      • London Agreement
      • National law relating to the EPC
      • Unitary patent system
      • National law relating to the UP
    • Court practices
      • Overview
      • European Patent Judges' Symposium
    • User consultations
      • Overview
      • Ongoing consultations
      • Completed consultations
    • Substantive patent law harmonisation
      • Overview
      • The Tegernsee process
      • Group B+
    • Convergence of practice
    • Options for professional representatives

    legal text

    Legal texts

  • News & events

    News & events

    Our latest news, podcasts and events, including the European Inventor Award.

    Go to overview 

     

    • Overview
    • News
    • Events
    • European Inventor Award
      • Overview
      • About the award
      • Categories and prizes
      • Meet the finalists
      • Nominations
      • Watch the 2022 ceremony
    • Press centre
      • Overview
      • Patent Index and statistics
      • Search in press centre
      • Background information
      • Copyright
      • Press contacts
      • Call back form
      • Email alert service
    • Innovation and patenting in focus
      • Overview
      • Firefighting technologies
      • Green tech in focus
      • CodeFest on Green Plastics
      • Clean energy technologies
      • IP and youth
      • Research institutes
      • Women inventors
      • Fighting coronavirus
      • Lifestyle
      • Space and satellites
      • The future of medicine
      • Materials science
      • Mobile communications
      • Biotechnology
      • Patent classification
      • Digital technologies
      • The future of manufacturing
      • Books by EPO experts
    • "Talk innovation" podcast

    Podcast

    Listen to our podcast

  • Learning

    Learning

    The e-Academy – the point of access to your learning

    Go to overview 

    • Overview
    • European Patent Academy
      • Overview
      • Learning activities
      • Learning paths
    • Professional hub
      • Overview
      • EQE - European qualifying examination
      • EPAC - European patent administration certification
    • Learning resources by area of interest
      • Overview
      • Patent granting
      • Technology transfer and dissemination
      • Patent enforcement and litigation
    • Learning resources by area by profile
      • Overview
      • Business and IP managers
      • EQE candidates
      • Judges, lawyers and prosecutors
      • National offices and IP authorities
      • Patent attorneys and paralegals
      • Universities, research centres and technology transfer centres (TTOs)

    European Patent Academy

    Boost your IP knowledge with (e-)training from the European Patent Academy

  • About us

    About us

    Find out more about our work, values, history and vision

    Go to overview 

    • Overview
    • The EPO at a glance
    • 50 years of the EPC
      • Overview
      • A glimpse of the planned activities
      • Kids’ collaborative art competition
      • 50 Leading Tech Voices
    • Legal foundations and member states
      • Overview
      • Legal foundations
      • Member states of the European Patent Organisation
      • Extension states
      • Validation states
    • Governance
      • Overview
      • Communiqués
      • Calendar
      • Select Committee documents
      • Administrative Council
    • Principles & strategy
      • Overview
      • Our mission, vision, values and corporate policy
      • Public consultation on the EPO's Strategic Plan 2028
      • Towards a New Normal
    • Leadership & management
      • Overview
      • President António Campinos
      • Management Advisory Committee
    • Social responsibility
      • Overview
      • Environment and sustainability
      • Art collection
    • Services & activities
      • Overview
      • Our services & structure
      • Consulting our users
      • European and international co-operation
      • European Patent Academy
      • Chief Economist
      • Ombuds Office
      • Reporting wrongdoing
    • Procurement
      • Overview
      • Procurement forecast
      • Doing business with the EPO
      • Procurement procedures
      • About eTendering and electronic signatures
      • Procurement portal
      • Invoicing
      • General conditions
      • Archived tenders
    • Transparency portal
      • Overview
      • General
      • Human
      • Environmental
      • Organisational
      • Social and relational
      • Economic
      • Governance
    • Statistics and trends
      • Overview
      • Statistics & Trends Centre
      • EPO Data Hub
      • Clarification on data sources
    • History
      • Overview
      • 1970s
      • 1980s
      • 1990s
      • 2000s
      • 2010s
      • 2020s

    about us

    Patent Index 2022

 
en de fr
  • Language selection
  • English
  • Deutsch
  • Français
Main navigation
  • Homepage
  • New to patents
    • Go back
    • Overview
    • What's your big idea?
    • Are you ready?
    • What to expect
    • How to apply for a patent
    • Your business and patents
    • Is it patentable?
    • Are you first?
    • Why do we have patents?
    • Patent quiz
    • Unitary patent video
  • Searching for patents
    • Go back
    • Overview
    • Technical information
      • Go back
      • Overview
      • Espacenet - patent search
        • Go back
        • Overview
        • National patent office databases
        • Global Patent Index (GPI)
        • Release notes
      • European Publication Server
        • Go back
        • Overview
        • Cross-reference index for Euro-PCT applications
        • EP authority file
        • Help
      • Searching Asian documents
      • EP full-text search
      • Bibliographic coverage in Espacenet and OPS
      • Full-text coverage in Espacenet
    • Legal information
      • Go back
      • Overview
      • European Patent Register
        • Go back
        • Overview
        • Release notes archive
        • Register documentation
          • Go back
          • Overview
          • Deep link data coverage
          • Federated Register
            • Go back
            • Overview
            • BG - Federated Register Service
            • GB - Federated Register Service
            • NL - Federated Register Service
            • MK - Federated Register Service
            • ES - Federated Register Service
            • GR - Federated Register Service
            • SK - Federated Register Service
            • FR - Federated Register Service
            • MT - Federated Register Service
          • Register events
      • European Patent Bulletin
        • Go back
        • Overview
        • Download Bulletin
        • EP Bulletin search
        • Help
      • European Case Law Identifier sitemap
      • Searching Asian documents
      • Third-party observations
    • Business information
      • Go back
      • Overview
      • PATSTAT
      • IPscore
        • Go back
        • Release notes
      • Patent insight reports
    • Data
      • Go back
      • Overview
      • Linked open EP data
      • Bulk data sets
        • Go back
        • Overview
        • Manuals
        • Sequence listings
        • National full-text data
        • European Patent Register data
        • EPO worldwide bibliographic data (DOCDB)
        • EP full-text data
        • EPO worldwide legal event data (INPADOC)
        • EP bibliographic data (EBD)
          • Go back
          • EBD files (weekly download) - free of charge
            • Go back
            • Secure EBD ST.36 files (weekly download) - for national patent offices only
        • Boards of Appeal decisions
        • EP full-text data for text analytics
      • Web services
        • Go back
        • Overview
        • Open Patent Services (OPS)
        • European Publication Server
      • Coverage, codes and statistics
        • Go back
        • Weekly updates
        • Updated regularly
    • Helpful resources
      • Go back
      • Overview
      • First time here? Patent information explained.
        • Go back
        • Overview
        • Basic definitions
        • Patent classification
          • Go back
          • Overview
          • Cooperative Patent Classification (CPC)
        • Patent families
          • Go back
          • Overview
          • DOCDB simple patent family
          • INPADOC extended patent family
        • Legal event data
          • Go back
          • Overview
          • INPADOC classification scheme
      • Asian patent information
        • Go back
        • Overview
        • China (CN)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Chinese Taipei (TW)
          • Go back
          • Overview
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • India (IN)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
        • Japan (JP)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Korea (KR)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Russian Federation (RU)
          • Go back
          • Overview
          • Facts and figures
          • Numbering system
          • Searching in databases
        • Useful links
      • Patent information centres (PATLIB)
      • Patent Translate
      • Patent Knowledge News
      • Business and statistics
      • Unitary Patent information in patent knowledge
  • Applying for a patent
    • Go back
    • Overview
    • European route
      • Go back
      • Overview
      • European Patent Guide
      • Oppositions
      • Oral proceedings
        • Go back
        • Oral proceedings calendar
          • Go back
          • Calendar
          • Public access to appeal proceedings
          • Public access to opposition proceedings
          • Technical guidelines
      • Appeals
      • Unitary Patent & Unified Patent Court
        • Go back
        • Overview
        • Unitary Patent
          • Go back
          • Overview
          • Legal framework
          • Unitary Patent Guide
          • Main features
          • Applying for a Unitary Patent
          • Cost of a Unitary Patent
          • Translation and compensation
          • Start date
        • Unified Patent Court
      • National validation
      • Extension/validation request
    • International route
      • Go back
      • Overview
      • Euro-PCT Guide
      • Entry into the European phase
      • Decisions and notices
      • PCT provisions and resources
      • Extension/validation request
      • Reinforced partnership programme
      • Accelerating your PCT application
      • Patent Prosecution Highway (PPH)
        • Go back
        • Patent Prosecution Highway (PPH) programme outline
      • Training and events
    • National route
    • MyEPO services
      • Go back
      • Overview
      • Understand our services
        • Go back
        • Overview
        • Online Filing 2.0 pilot
        • MyEPO Portfolio - pilot phase
        • Online Filing 2.0 pilot continuation
        • Exchange data with us using an API
      • Get access
        • Go back
        • Overview
        • Installation and activation
      • Find a professional representative
      • File with us
        • Go back
        • Overview
        • What if our online filing services are down?
        • Release notes
      • Interact on your files
      • Online Filing & fee payment outages
      • Tutorials
    • Fees
      • Go back
      • Overview
      • European fees (EPC)
        • Go back
        • Overview
        • Decisions and notices
      • International fees (PCT)
        • Go back
        • Reduction in fees
        • Fees for international applications
        • Decisions and notices
        • Overview
      • Unitary Patent fees (UP)
        • Go back
        • Overview
        • Decisions and notices
      • Fee payment and refunds
        • Go back
        • Overview
        • Payment methods
        • Getting started
        • FAQs and other documentation
        • Technical information for batch payments
        • Decisions and notices
        • Release notes
      • Warning
    • Forms
      • Go back
      • Request for examination
  • Law & practice
    • Go back
    • Overview
    • Legal texts
      • Go back
      • Overview
      • European Patent Convention
        • Go back
        • Overview
        • Archive
          • Go back
          • Overview
          • Documentation on the EPC revision 2000
            • Go back
            • Overview
            • Diplomatic Conference for the revision of the EPC
            • Travaux préparatoires
            • New text
            • Transitional provisions
            • Implementing regulations to the EPC 2000
            • Rules relating to Fees
            • Ratifications and accessions
          • Travaux Préparatoires EPC 1973
      • Official Journal
      • EPC Guidelines
        • Go back
        • Overview
        • Archive
      • PCT-EPO Guidelines
        • Go back
        • Overview
        • Archive
      • Guidelines revision cycle
      • Extension / validation system
      • London Agreement
      • National law relating to the EPC
        • Go back
        • Overview
        • Archive
      • Unitary Patent system
      • National measures relating to the Unitary Patent 
    • Court practices
      • Go back
      • Overview
      • European Patent Judges' Symposium
    • User consultations
      • Go back
      • Overview
      • Ongoing consultations
      • Completed consultations
    • Substantive patent law harmonisation
      • Go back
      • Overview
      • The Tegernsee process
      • Group B+
    • Convergence of practice
    • Options for professional representatives
  • News & events
    • Go back
    • Overview
    • News
    • Events
    • European Inventor Award
      • Go back
      • Overview
      • About the award
      • Categories and prizes
      • Meet the finalists
      • Nominations
      • Watch the 2023 ceremony
      • European Inventor Network
        • Go back
        • Activities granted in 2023
    • Press centre
      • Go back
      • Overview
      • Patent Index and statistics
      • Search in press centre
      • Background information
        • Go back
        • Overview
        • European Patent Office
        • Q&A on patents related to coronavirus
        • Q&A on plant patents
      • Copyright
      • Press contacts
      • Call back form
      • Email alert service
    • In focus
      • Go back
      • Overview
      • Firefighting technologies
        • Go back
        • Overview
        • Detection and prevention of fires
        • Fire extinguishing
        • Protective equipment
        • Post-fire restoration
      • Green tech in focus
        • Go back
        • Overview
        • About green tech
        • Renewable energies
        • Energy transition technologies
        • Building a greener future
      • CodeFest on Green Plastics
      • Clean energy technologies
        • Go back
        • Overview
        • Renewable energy
        • Carbon-intensive industries
        • Energy storage and other enabling technologies
      • IP and youth
      • Research institutes
      • Women inventors
      • Fighting coronavirus
        • Go back
        • Overview
        • Vaccines and therapeutics
          • Go back
          • Overview
          • Vaccines
          • Overview of candidate therapies for COVID-19
          • Candidate antiviral and symptomatic therapeutics
          • Nucleic acids and antibodies to fight coronavirus
        • Diagnostics and analytics
          • Go back
          • Overview
          • Protein and nucleic acid assays
          • Analytical protocols
        • Informatics
          • Go back
          • Overview
          • Bioinformatics
          • Healthcare informatics
        • Technologies for the new normal
          • Go back
          • Overview
          • Devices, materials and equipment
          • Procedures, actions and activities
          • Digital technologies
        • Inventors against coronavirus
      • Lifestyle
      • Space and satellites
        • Go back
        • Overview
        • Patents and space technologies
      • Healthcare
        • Go back
        • Overview
        • Medical technologies and cancer
        • Personalised medicine
      • Materials science
        • Go back
        • Overview
        • Nanotechnology
      • Mobile communications
      • Biotechnology
        • Go back
        • Overview
        • Red, white or green
        • The role of the EPO
        • What is patentable?
        • Biotech inventors
      • Classification
        • Go back
        • Overview
        • Nanotechnology
        • Climate change mitigation technologies
          • Go back
          • Overview
          • External partners
          • Updates on Y02 and Y04S
      • Digital technologies
        • Go back
        • Overview
        • About ICT
        • Hardware and software
        • Patents and standards
        • Artificial intelligence
        • Fourth Industrial Revolution
      • Additive manufacturing
        • Go back
        • Overview
        • About AM
        • AM innovation
      • Books by EPO experts
    • Podcast
  • Learning
    • Go back
    • Overview
    • European Patent Academy
      • Go back
      • Overview
      • Learning activities
      • Learning Paths
    • Professional hub
      • Go back
      • Overview
      • EPAC - European patent administration certification
      • EQE - European Qualifying Examination
        • Go back
        • Overview
        • Archive
        • Candidates successful in the European qualifying examination
        • Compendium
          • Go back
          • Overview
          • Pre-examination
          • Paper A
          • Paper B
          • Paper C
          • Paper D
    • Learning resources by area of interest
      • Go back
      • Overview
      • Patent granting
      • Technology transfer and dissemination
      • Patent enforcement and litigation
        • Go back
        • Overview
        • Patent enforcement in Europe
        • Patent litigation in Europe
    • Learning resources by profile
      • Go back
      • Overview
      • Business and IP managers
        • Go back
        • Overview
        • Innovation case studies
          • Go back
          • Overview
          • SME case studies
          • Technology transfer case studies
          • High-growth technology case studies
        • Inventors' handbook
          • Go back
          • Overview
          • Introduction
          • Disclosure and confidentiality
          • Novelty and prior art
            • Go back
            • Overview
            • Is the idea ‘obvious’?
            • Prior art searching
            • Professional patent searching
            • Simple Espacenet searching
            • What is prior art?
            • Why is novelty important?
          • Competition and market potential
            • Go back
            • Overview
            • Research guidelines
          • Assessing the risk ahead
            • Go back
            • Overview
            • Exploitation routes
            • Significant commercial potential
            • Significant novelty
            • What about you?
            • What if your idea is not novel but does have commercial potential?
          • Proving the invention
            • Go back
            • Overview
            • Help with design or redesign
            • Prototype strategy
          • Protecting your idea
            • Go back
            • Overview
            • Forms of IPR
            • Patenting strategy
            • The patenting process
          • Building a team and seeking funding
            • Go back
            • Overview
            • Building a team
            • Sources of funding
            • Sources of help for invention
          • Business planning
            • Go back
            • Overview
            • Constructing a business plan
            • Keep it short!
          • Finding and approaching companies
            • Go back
            • Overview
            • First contact
            • Meetings
          • Dealing with companies
            • Go back
            • Overview
            • Advance or guaranteed payment
            • Companies and your prototype
            • Full agreement – and beyond
            • Negotiating a licensing agreement
            • Reaching agreement
            • Royalties
        • Best of search matters
          • Go back
          • Overview
          • Tools and databases
          • EPO procedures and initiatives
          • Search strategies
          • Challenges and specific topics
        • Support for high-growth technology businesses
          • Go back
          • Overview
          • For IP professionals
          • For business decision-makers
          • For stakeholders of the innovation ecosystem
        • IP clinics
      • EQE Candidates
        • Go back
        • Overview
        • Coffee-break questions
        • Daily D questions
        • European qualifying examination - Guide for preparation
      • Judges, lawyers and prosecutors
        • Go back
        • Overview
        • Compulsory licensing in Europe
        • The jurisdiction of European courts in patent disputes
      • National offices and IP authorities
        • Go back
        • Overview
        • Learning material for examiners of national officers
        • Learning material for formalities officers and paralegals
      • Patent attorneys and paralegals
      • Universities, research centres and TTOs
        • Go back
        • Overview
        • Academic Research Programme
          • Go back
          • Overview
          • Completed research projects
          • Current research projects
        • Pan-European Seal Young Professionals Programme
          • Go back
          • Overview
          • For students
          • For universities
            • Go back
            • Overview
            • IP education resources
            • University memberships
          • Our young professionals
          • Professional development plan
        • IP Teaching Kit
          • Go back
          • Overview
          • Download modules
        • Intellectual property course design manual
  • About us
    • Go back
    • Overview
    • The EPO at a glance
    • 50 years of the EPC
      • Go back
      • Overview
      • 50 Leading Tech Voices
      • Kids’ collaborative art competition
    • Legal foundations and member states
      • Go back
      • Overview
      • Legal foundations
      • Member states
        • Go back
        • Overview
        • Member states by date of accession
      • Extension states
      • Validation states
    • Governance
      • Go back
      • Overview
      • Communiqués
        • Go back
        • Overview
        • 2022
        • 2021
        • 2020
        • 2019
        • 2018
        • 2017
        • 2016
        • 2015
        • 2014
        • 2013
      • Calendar
      • Documents and publications
        • Go back
        • Overview
        • Select Committee documents
      • Administrative Council
        • Go back
        • Overview
        • Composition
        • Representatives
        • Rules of Procedure
        • Board of Auditors
        • Secretariat
        • Council bodies
    • Principles & strategy
      • Go back
      • Overview
      • Mission, vision, values & corporate policy
      • Strategic Plan 2028
      • Towards a New Normal
      • Data protection & privacy notice
    • Leadership & management
      • Go back
      • Overview
      • About the President
      • Management Advisory Committee
    • Procurement
      • Go back
      • Overview
      • Procurement forecast
      • Doing business with the EPO
      • Procurement procedures
      • About eTendering
      • Procurement portal
        • Go back
        • Overview
        • e-Signing contracts
      • Invoicing
      • General conditions
      • Archived tenders
    • Services & activities
      • Go back
      • Overview
      • Our services & structure
      • Quality
        • Go back
        • Overview
        • Foundations
          • Go back
          • Overview
          • European Patent Convention
          • Guidelines for examination
          • Our staff
        • Enabling quality
          • Go back
          • Overview
          • Prior art
          • Classification
          • Tools
          • Processes
        • Products & services
          • Go back
          • Overview
          • Search
          • Examination
          • Opposition
          • Continuous improvement
        • Quality through networking
          • Go back
          • Overview
          • User engagement
          • Co-operation
          • User satisfaction survey
          • Stakeholder Quality Assurance Panels
        • Patent Quality Charter
        • Statistics
          • Go back
          • Overview
          • Search
          • Examination
          • Opposition
      • Consulting our users
        • Go back
        • Overview
        • Standing Advisory Committee before the EPO (SACEPO)
          • Go back
          • Overview
          • Objectives
          • SACEPO and its working parties
          • Meetings
          • Single Access Portal – SACEPO Area
      • Our user service charter
      • European and international co-operation
        • Go back
        • Overview
        • Co-operation with member states
          • Go back
          • Overview
        • Bilateral co-operation with non-member states
          • Go back
          • Overview
          • Validation system
          • Reinforced Partnership programme
        • Multilateral international co-operation with IP offices and organisations
        • Co-operation with international organisations outside the IP system
      • European Patent Academy
        • Go back
        • Overview
        • Partners
      • Chief Economist
        • Go back
        • Overview
        • Economic studies
      • Ombuds Office
      • Reporting wrongdoing
    • Statistics and trends
      • Go back
      • Overview
      • Statistics & Trends Centre
      • EPO Data Hub
      • Clarification on data sources
    • Social responsibility
      • Go back
      • Overview
      • Environment
      • Art collection
        • Go back
        • Overview
        • The collection
        • Let's talk about art
        • Artists
        • Media library
        • What's on
        • Publications
        • Contact
    • History
      • Go back
      • Overview
      • 1970s
      • 1980s
      • 1990s
      • 2000s
      • 2010s
      • 2020s
    • Transparency portal
      • Go back
      • Overview
      • General
        • Go back
        • Overview
        • Annual Review 2022
          • Go back
          • Overview
          • Foreword
          • Executive summary
          • Goal 1: Engaged and empowered
          • Goal 2: Digital transformation
          • Goal 3: Master quality
          • Goal 4: Partner for positive impact
          • Goal 5: Secure sustainability
      • Human
      • Environmental
      • Organisational
      • Social and relational
      • Economic
      • Governance
  • Boards of Appeal
    • Go back
    • Overview
    • Decisions of the Boards of Appeal
      • Go back
      • Overview
      • Recent decisions
      • Selected decisions
    • Procedure
    • Annual reports
      • Go back
      • Overview
    • Organisation
      • Go back
      • Overview
      • President of the Boards of Appeal
      • Enlarged Board of Appeal
        • Go back
        • Overview
        • Pending referrals (Art. 112 EPC)
        • Decisions sorted by number (Art. 112 EPC)
        • Pending petitions for review (Art. 112a EPC)
        • Decisions on petitions for review (Art. 112a EPC)
      • Technical Boards of Appeal
      • Legal Board of Appeal
      • Disciplinary Board of Appeal
      • Presidium
        • Go back
        • Overview
        • Composition of the Presidium
          • Go back
          • Overview
          • Archive
    • Code of Conduct
    • Business distribution scheme
      • Go back
      • Overview
      • Technical boards of appeal by IPC in 2023
      • Archive
    • Annual list of cases
    • Communications
    • Publications
    • Case Law of the Boards of Appeal
      • Go back
      • Overview
      • Archive
    • Case Law from the Contracting States to the EPC
    • Oral proceedings
  • Service & support
    • Go back
    • Overview
    • Website updates
    • Availability of online services
      • Go back
      • Overview
    • FAQ
      • Go back
      • Overview
    • Publications
    • Ordering
      • Go back
      • Overview
      • Terms and conditions
        • Go back
        • Overview
        • Patent information products
        • Bulk data sets
        • Open Patent Services (OPS)
        • Fair use charter
    • Procedural communications
    • Useful links
      • Go back
      • Overview
      • Patent offices of member states
      • Other patent offices
      • Legal resources
      • Directories of patent attorneys
      • Patent databases, registers and gazettes
      • Disclaimer
    • Contact us
      • Go back
      • Overview
      • Filing options
      • Locations
      • Specific contact
      • Surveys
        • Go back
        • Overview
        • Search services
        • Examination services, final actions and publication
        • Opposition services
        • Patent filings
          • Go back
          • Overview
          • Detailed methodology
          • Archive
        • Online Services
        • Patent information
          • Go back
          • Overview
          • Innovation process survey
        • Customer services
        • Filing services
        • Website
        • Survey on electronic invoicing
        • Companies innovating in clean and sustainable technologies
    • Subscription centre
      • Go back
      • Overview
      • Subscribe
      • Change preferences
      • Unsubscribe
    • Official holidays
    • Forums
    • Glossary
Board of Appeals
Decisions

Recent decisions

Overview
  • 2023 decisions
  • 2022 decisions
  • 2021 decisions
https://www.epo.org/en/node/t060025eu1
  1. Home
  2. T 0025/06 (Botulinum toxin/SOLSTICE NEUROSCIENCES) 10-10-2007
Facebook Twitter Linkedin Email

T 0025/06 (Botulinum toxin/SOLSTICE NEUROSCIENCES) 10-10-2007

European Case Law Identifier
ECLI:EP:BA:2007:T002506.20071010
Date of decision
10 October 2007
Case number
T 0025/06
Petition for review of
-
Application number
99945649.4
IPC class
A61K 38/16
Language of proceedings
EN
Distribution
DISTRIBUTED TO BOARD CHAIRMEN (C)

Download and more information:

Decision in EN 38.06 KB
Documentation of the appeal procedure can be found in the European Patent Register
Bibliographic information is available in:
EN
Versions
Unpublished
Application title

Stable liquid formulations of botulinum toxin

Applicant name
Solstice Neurosciences, Inc.
Opponent name
Société de Conseils de Recherches et d'Applications Scientifiques (S.C.R.A.S.)
Board
3.3.04
Headnote
-
Relevant legal provisions
European Patent Convention Art 123(2) 1973
European Patent Convention Art 123(3) 1973
European Patent Convention Art 84 1973
European Patent Convention Art 111(1) 1973
European Patent Convention R 57 1973
Keywords
Main request: Added subject-matter (no); Broadening of the scope of protection (no); Clarity and support in the description (yes); Amendments acc.. by the grounds of opposition (yes); Remittal (yes)
Catchword
-
Cited decisions
-
Citing decisions
-

I. European Patent No. 1 112 082 based on application No. 99 945 649.4 (published as WO 00/15245) and having the title "Stable liquid formulations of botulinum toxin" was granted on the basis of 23 claims, of which claim 1 read as follows:

"1. A stable liquid pharmaceutical botulinum toxin formulation, comprising a pharmaceutically acceptable buffer capable of providing a buffered pH range between about pH 5 and pH 6, and isolated botulinum toxin; wherein said formulation is stable as a liquid for at least one year at a temperature between about 0 and 10ºC, or at least 6 months at a temperature between about 10 and 30ºC."

II. Notices of opposition were filed by opponents O1 and O2 requesting the revocation of the European patent on the grounds of lack of novelty, lack of inventive step and insufficiency of disclosure (Article 100(a) and (b) EPC).

III. The opposition division only dealt with the formal admissibility under Articles 123 and 84 EPC of the claims of the Main Request and of the 1st to 7th Auxiliary Requests then before it, which was denied on the grounds that claim 1 of all these requests included the expression "buffered saline" which was said to be unclear and not originally disclosed. Hence the patent was revoked.

IV. The appellant (patentee) filed an appeal against the decision of the opposition division. The grounds of appeal included a Main Request and an Auxiliary Request I. Claims 1 and 11 of the Main Request read as follows:

"1. A stable, ready-to-use liquid pharmaceutical formulation comprising serum albumin; a pharmaceutically acceptable buffered saline which provides a buffered pH range between pH 5 and pH 6; and isolated botulinum toxin that is stable in said formulation for at least one year at a temperature between about 0 and 10ºC, or for at least 6 months at a temperature between about 10 and 30ºC."

"11. The formulation of claim 10, wherein the stable, ready-to-use liquid pharmaceutical formulation comprises 100 mM sodium chloride; 10 mM succinate buffer at a buffered pH of 5.6; 0.5 mg/mL human serum albumin; and botulinum type B present at a concentration of 5,000 ± 1000 U/ml."

Claims 2 to 10 related to specific embodiments of the formulation according to claim 1. Claims 12 to 22 were directed to medical uses of the formulation of claim 1 in Swiss type claim format.

V. The following documents are cited in the present decision:

D1 Goodnough M.C. et al., Applied and Environmental Microbiology, Vol. 58, No. 10, pages 3426-3428 (1992);

D12 US-A-5,714,468;

D17 McLellan, K. et al., Toxicon, Vol. 34, No. 9, page 975-985 (1996);

D19 Schantz E.J. and Johnson E.A. in Therapy with Botulinum Toxin, edited by Joseph Jankovic and Mark Hallett, Marcel Dekker, New York, Basel, Hong Kong, pages 41-49 (1994);

D24 Asher B., J. Méd. Esth. et Chir. Derm., Vol.

XXIII, pages 159-166 (1996);

D33 Schantz E.J. et al., Journal of the AOAC, Vol. 61, No. 1, pages 96-99 (1978).

VI. The appellant's arguments in writing and during the oral proceedings, insofar as they are relevant to the present decision, may be summarized as follows:

Main request

Rule 57 EPC

- The amendments had been occasioned by the grounds of opposition specified in Article 100 EPC.

Article 123(2)(3) EPC

"Buffered saline"

- Support for the term "buffered saline which provides a buffered pH range between pH 5 and pH 6" could be found on page 7, lines 3 to 7 of the published WO application in combination with Example 1 on pages 19 ff. and the statement on page 28, lines 24 and 25, of the published WO application.

- There was a basis for the expression "buffered saline" in claim 1 on the grounds that (i) the "buffered saline" was a component of the liquid pharmaceutical formulation as claimed; (ii) the term "buffer" also related to a salt solution; (iii) a saline alone, while providing the required osmotic value, would not achieve any buffering capacity; and (iv) the term "buffered saline" was synonymous with "physiological sodium chloride solution".

"Stability requirement"

- According to page 6, lines 1 to 3 of the published WO application, "stable" related to the retention of biological activity or potency by the botulinum toxin.

Article 84 EPC

"Buffered saline"

- The skilled person would understand that the term "saline" could only mean "physiological sodium chloride solution".

"Ready-to-use"

- The term "ready-to-use" meant that the liquid pharmaceutical formulation could be used as needed by the clinician, without further reconstitution. This interpretation was in line with the remaining disclosure in the patent in suit.

VII. After having raised objections, inter alia, under Rule 57, Articles 84 and 123(2)(3) EPC against the claims of the main request (see the "reasons" for more details), the respondents (opponents O1 and O2) withdrew their oppositions with letters dated 8 October 2007 and 18 May 2007, respectively.

VIII. The appellant requested that the decision under appeal be set aside and that the patent be maintained in amended form on the basis of claims 1 to 22 of the main request filed with the grounds of appeal dated 3 April 2006, with the proviso that claim 11 is made dependent not from claim 10 but from claim 1.

Main request

1. At the appeal stage up to the withdrawal of their oppositions, the respondents (opponents O1 and O2) raised objections, inter alia, under Rule 57(a), Articles 84 and 123(2)(3) EPC against the claims of this request. The board will consider in the following whether or not any of these objections were justified.

Rule 57 EPC

2. The respondents objected to the introduction of dependent claim 11 as being not occasioned by any ground of opposition.

Following the change in claim dependency requested by the appellant (see paragraph VIII supra), claim 11 relates to a specific embodiment of the composition according to claim 1, wherein the parameters correspond to those of the composition of Example 1B of the patent in suit. Claim 11 thus serves to further adequately interpret claim 1 and may be considered as being occasioned by the grounds of oppositions, i.e., the novelty-destroying prior art documents D1, D12 to D19, D24 and D33. Therefore, since the introduction of claim 11 is occasioned by the grounds of opposition specified in Article 100 EPC, the board concludes the requirements of Rule 57 EPC are met.

Article 123(2)(3) EPC

"Buffered saline"

3. In the respondents' opinion, there was no basis for the expression "buffered saline" in claim 1 on the grounds that (i) the buffered saline was not part of the formulation, but only something in which the formulation could be stored (see page 7, first full paragraph of the published WO application); (ii) the term "buffer" related to the salt, not to the solution of a salt; (iii) since "buffer" and "saline" were separate entities, the term "buffered saline" could be interpreted as a saline devoid of buffer; and (iv) "buffered saline" was not synonymous with "physiological buffer" but rather alternative thereto.

4. As regards ground (i) above (the buffered saline was not part of the formulation), it is stated on page 7, first full paragraph of the published WO application, that the "liquid pharmaceutical formulation" can be stored in a "buffered saline". Therefore, in the board's judgement, once said "liquid pharmaceutical formulation" is stored in a "buffered saline", the latter becomes a component of the liquid pharmaceutical formulation as claimed, as illustrated by Table 1 of Example 1 (see ibidem, page 19), describing the preparation of a ready-to-use stable botulinum toxin formulation wherein the buffered saline (10 mM succinate + 100 mM sodium chloride) is part of the formulation. Hence, there is a basis in the published WO application for a "liquid pharmaceutical formulation comprising a buffered saline".

5. As for ground (ii) above (the term "buffer" related to the salt, not to the solution of a salt), the term "buffer" relates both to the salt (see page 13, lines 14-16 of the published WO application: "succinate, phosphate, acetate, citrate, aconitate, malate and carbonate") prior to its dissolution and the solution comprising said salt (see ibidem, page 7, lines 8-9: "a salt, which, when dissolved in an aqueous medium"). Moreover, it is only in solution that a salt can exert its buffering capacities (transfer of hydrogen ions). Therefore, the term "buffer" within the context of the published WO application also relates to a salt solution.

6. As for ground (iii) above ("buffered saline" could be interpreted a saline devoid of buffer, since "buffer" and "saline" were separate entities), the board is unable to find a basis in the published WO application for interpreting the term "buffered saline" as a saline devoid of buffer. This interpretation also does not make technical sense because, while a saline alone would provide a particular osmotic value, it would not achieve the buffering capacity required by present claim 1.

7. As regards ground (iv) above ("buffered saline" was not synonymous with "physiological buffer" but rather alternative thereto), the board views a "buffered saline" as a particular kind of "physiological buffer". The latter term is defined on page 7, lines 13 to 15, of the published WO application as a buffer that is non-toxic when administered as part of a pharmaceutical preparation. A prerequisite for a physiological buffer to be non-toxic is that it must be isotonic with blood. To this effect, the desired osmolarity is achieved by the presence of a given amount of saline. This view is supported by Example 1A describing a 0.85% w/v buffered saline ([2.7 + 5.8]mg/ml = 8.5 mg/ml = 0.85 g/100 ml = 0.85 g/100 g), in keeping with the 0.85% w/v NaCl normally added to get a physiological solution (see e.g. document D17, page 977 under "Bioassay for botulin toxin A", last sentence).

"Stability requirement"

8. The respondents raised an objection that new matter had been added by changing the stability requirement in present claim 1 from "wherein said formulation is stable" (granted claim 1) to "botulinum toxin that is stable in said formulation". However, according to page 6, lines 1 to 3 of the published WO application, "stable" refers to the retention of biological activity or potency by the botulinum toxin. Moreover, Example 2 of the published WO application describes assays to determine the stability by measuring the potency of the botulinum toxin in the claimed liquid formulations. Therefore, the wording "botulinum toxin that is stable in said formulation" in present claim 1 has a basis in the application as filed.

9. The respondents also considered the above amendment as violating Article 123(3) EPC, arguing that present claim 1 covered formulation not covered by granted claim 1, wherein the instability in the formulation was not caused by the toxin itself.

It follows from the above board's conclusion in relation to Article 123(2) EPC that granted claim 1 cannot not cover formulations where the instability is not caused by the botulinum toxin itself. Therefore, no problem under Article 123(3) EPC arises, either, since claim 1 of the Main Request does not cover formulations that were not covered by the granted claims.

10. In conclusion, the claims satisfy the requirements of Article 123(2)(3) EPC.

Article 84 EPC

"Buffered saline"

11. The respondents argued that this term was not synonymous with "physiological sodium chloride solution" but could also refer to any salt solution, such as e.g. a magnesium sulfate containing solution.

However, in the board's judgement, the skilled person would understand that the term "saline" can only mean "physiological sodium chloride solution" in the sense of Example 1A of the patent describing a 0.85% w/v buffered saline and of the 0.85% w/v NaCl physiological solution referred to in e.g. document D17, page 977 under "Bioassay for botulin toxin A", last sentence (see point 7 supra). This is because the limitation introduced by the phrase "pharmaceutically acceptable" in present claim 1 precludes salts that are not isotonic (causing a possible haemolysis),or that may be toxic upon administration, such as magnesium sulfate.

"Ready-to-use"

12. The respondents maintained that the term "ready-to-use" lacked clarity. If the above expression meant that the liquid formulation could be used immediately on a patient, in the respondents' view, this interpretation was contradicted by paragraph [0022] of the patent, stating that the formulation could be a concentrated formulation to be diluted in a similar or different liquid prior to use.

Paragraph [0005] of the patent in suit discusses the disadvantages of the prior art botulinum toxin formulations, inter alia, the fact that a physician wishing to administer botulinum toxin had to reconstitute it immediately prior to use (see also page 4, lines 6 to 9 of the specification).

The term "ready-to-use" turns up for the first time in paragraph [0006] of the specification and provides the definition of the expression "ready-to-use liquid pharmaceutical formulation" as being a formulation that can be used as needed by the clinician, without further reconstitution. This interpretation is line with the remaining disclosure in the patent in suit (see for example, paragraph [0040], line 9: "without further re-constitution by the physician"). Therefore, the term "ready-to-use" is not obscure to the skilled person.

13. The respondents argued that paragraph [0022] of the patent ("concentrated formulation which is diluted") contradicted the definition of the term "ready-to-use" as meaning "liquid formulation that can be could be used immediately on a patient".

However, although according to the above embodiment of paragraph [0022] of the patent the claimed liquid formulation may comprise concentrated amounts of toxin that need to be diluted by the physician for convenience, these concentrated formulations themselves do not need to be reconstituted by the physician from lyophilized toxin before administration to a patient (rather than being susceptible of "immediate use on a patient", as argued by the respondents). Therefore, the board does not see the contradiction pointed out by the respondents.

14. In view of the foregoing, the claims of the main request fulfil the requirements of Article 84 EPC.

Remittal

15. In the decision under appeal, the opposition division only dealt with the formal admissibility under Articles 123 and 84 EPC of claims different from the claims presently on file. For the purpose of the present decision the board has already examined the claims of the new Main Request as to whether or not they fulfil the requirements of Rule 57 and Articles 123(2)(3) and 84 EPC (see points 2 to 14 supra), but, in order not to deprive the appellant of the possibility to have his invention examined by two instances, and in accordance with the established jurisprudence of the boards of appeal, the board uses its discretion under Article 111(1), second sentence, EPC, and remits the case to the first instance for further prosecution to consider the remaining issues.

Order

ORDER

For these reasons it is decided that:

1. The decision under appeal is set aside.

2. The case is remitted to the department of first instance for further prosecution on the basis of claims 1 to 22 of the main request filed with the grounds of appeal dated 3 April 2006, with the proviso that claim 11 is made dependent not from claim 10 but from claim 1.

Footer - Service & support
  • Service & support
    • FAQ
    • Contact us
    • Subscription centre
    • Official holidays
    • Publications
    • Procedural communications
    • Ordering
    • Glossary
Footer - More links
  • Jobs & careers
  • Press centre
  • Single Access Portal
  • Procurement
  • Boards of Appeal
SoMe facebook 0
European Patent Office
EPO Jobs
SoMe instagram
EuropeanPatentOffice
SoMe linkedIn
European Patent Office
EPO Jobs
EPO Procurement
SoMe twitter
EPOorg
EPOjobs
SoMe youtube
TheEPO
Footer
  • Legal notice
  • Terms of use
  • Data protection and privacy
  • Accessibility